Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
AssigneeBiogen Idec MA Inc.
InventorsJeffrey L. Browning, Werner Meier, Christopher D. Benjamin
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-β receptor) activating agents where at least one LT-β receptor activating agent is an anti-LT-β receptor antibody.
Claims132
A method for treating or reducing the advancement, severity or effects of neoplasia comprising administering a therapeutically effective amount of at least two compositions, each composition comprising at least one anti-LT-β-R antibody and a pharmaceutically acceptable carrier, wherein each anti-LT-β-R antibody is directed to a different epitope.
A pharmaceutical composition comprising a therapeutically effective amount of at least two anti-LT-β-R antibodies, and a pharmaceutically acceptable carrier, wherein each anti-LT-β-R antibody is directed to a different epitope.
A method for treating or reducing the advancement, severity or effects of neoplasia comprising administering an effective amount of a pharmaceutical composition comprising an anti-LT-β-R antibody and a pharmaceutically acceptable carrier, wherein the composition is administered in the presence of an exogenous LT-β-R activating agent selected from the group consisting of IFN-α, TNF, and an anti-LT-β-R antibody.
Dependencies are inferred from the claim text.